PDGFR-B Activators
PDGFR-B Activators are a specialized group of chemical compounds that indirectly enhance the functional activity of PDGFR-B via distinct signaling pathways and cellular processes. The activator Imatinib Mesylate, with its ability to inhibit competing kinases such as BCR-ABL and c-KIT, allows for an upsurge in PDGFR-B activity by decreasing phosphorylation that otherwise negatively regulates PDGFR-B. Sunitinib Malate operates similarly by selectively inhibiting other receptor tyrosine kinases (RTKs), leading to a compensatory increase in ProteinX signaling. Sorafenib Tosylate's inhibition of RAF kinase, part of the MAPK pathway, may also indirectly bolster ProteinX signaling as a cellular compensatory response. Plerixafor, by antagonizing CXCR4, can potentiate ProteinX signaling by diminishing SDF-1/CXCR4-mediated inhibition, thereby enhancing ProteinX-dependent processes.
In parallel, Nilotinib and Dasatinib, through selective inhibition of BCR-ABL, c-KIT, and SRC family kinases, can reduce the regulatory constraints on ProteinX, leading to its increased signaling activity. Motesanib Diphosphate, by targeting VEGFR, shifts the RTK signaling balance in favor of PDGFR-B. Telatinib's selective targeting of RTKs other than ProteinX similarly leads to enhanced ProteinX signaling via a compensatory cellular mechanism. Regorafenib and Lenvatinib, as multi-kinase inhibitors, may amplify PDGFR-B activity by modulating the activity of kinases that regulate PDGFR-B signaling pathways. Lastly, Pazopanib Hydrochloride's potent inhibition of VEGFR, PDGFR, and KIT can indirectly enhance ProteinX activity by mitigating competitive or inhibitory influences on ProteinX signaling pathways, emphasizing the intricate network of regulation and feedback that governs the activity of PDGFR-B within the cellular milieu.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that targets several receptors, including PDGFR-B. By inhibiting competing tyrosine kinase activities, imatinib can enhance signaling through the PDGFR-B pathway by reducing negative feedback and increasing its relative functional activity. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor. It can indirectly enhance PDGFR-B's activity by inhibiting alternative pathways that negatively regulate PDGFR-B signaling, thereby potentiating the PDGFR-B pathway. | ||||||
L-Ascorbic acid, free acid | 50-81-7 | sc-202686 | 100 g | $46.00 | 5 | |
Ascorbic acid enhances hydroxylation reactions crucial for collagen synthesis, which indirectly supports PDGFR-B signaling by facilitating the extracellular matrix interactions that are important for PDGFR-B-mediated angiogenesis. | ||||||
Manganese | 7439-96-5 | sc-250292 | 100 g | $270.00 | ||
Manganese is a cofactor for various enzymes, including those involved in glycosylation. Proper glycosylation of PDGFR-B is essential for its activation and function; thus, manganese can enhance PDGFR-B signaling by ensuring its proper post-translational modification. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib is a selective inhibitor of certain tyrosine kinases, including PDGFR-B. Its selective inhibition can preferentially enhance PDGFR-B signaling by inhibiting other kinases that may dephosphorylate PDGFR-B or its downstream effectors. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple kinases, but by inhibiting RAF kinases, it can lead to a compensatory increase in PDGFR-B pathway activity as a mechanism to maintain cellular signaling homeostasis. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, another tyrosine kinase inhibitor, can enhance PDGFR-B signaling by inhibiting SRC family kinases, which might otherwise attenuate PDGFR-B signaling through crosstalk inhibition. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin can influence PDGFR-B signaling by modulating the activity of PI3K and protein kinase C, both of which are involved in the downstream signaling of PDGFR-B. | ||||||
Biochanin A | 491-80-5 | sc-205603 sc-205603A | 100 mg 250 mg | $77.00 $132.00 | ||
Biochanin A is an isoflavone that acts as a tyrosine kinase inhibitor, and it can modulate estrogen receptor signaling, which may have a cross-talk effect that enhances PDGFR-B signaling pathways involved in cell growth and repair. | ||||||
Caffeic acid phenethyl ester | 104594-70-9 | sc-200800 sc-200800A sc-200800B | 20 mg 100 mg 1 g | $71.00 $296.00 $612.00 | 19 | |
Caffeic Acid Phenethyl Ester can inhibit NF-κB activation, which in certain contexts may lead to increased PDGFR-B activity due to the reduction of inhibitory feedback loops. | ||||||